SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy for treating B-cell tumors. We evaluated the efficacy of TW-37, a non-peptidic SMI of Bcl-2...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Al-Katib, Ayad M, Sun, Yuan, Goustin, Anton Scott, Azmi, Asfar Sohail, Chen, Ben, Aboukameel, Amro, Mohammad, Ramzi M
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2009
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2651908/
https://ncbi.nlm.nih.gov/pubmed/19220884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-8
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים